iBio FY2026: $33M Net Loss, Cash Runway to FY2028, and New Amylin License
IBIO sits 86% above its 52-week low of $0.76.
Summary
iBio reported a $33.0 million FY2026 net loss with cash runway extended to fiscal 2028, disclosed a new Amylin license with AstralBio, and fully impaired its legacy IBIO-101 asset.
Key Events · Earnings and Guidance · IBIO
-
FY2026 Net Loss Widens to $33.0M
Net loss of $33.0 million for fiscal 2026, up from $18.4 million in fiscal 2025, driven by an $11.3 million increase in R&D expenses to $19.6 million.
-
Cash Runway Extended to FY2028
Cash, cash equivalents, and investments in debt securities totaled $88.0 million as of June 30, 2026, which management states extends the cash runway into the fourth quarter of fiscal 2028.
-
New Amylin License with AstralBio
On August 27, 2026, iBio entered into an exclusive worldwide license for an Amylin-targeting antibody with a $750,000 upfront fee and up to $28 million in milestone payments, payable in cash or equity subject to a 19.9% ownership cap.
-
Full $5.0M Impairment of IBIO-101
iBio recorded a total $5.0 million impairment of its legacy IBIO-101 oncology intangible asset in fiscal 2026, reflecting the strategic pivot to obesity and cardiometabolic diseases.
Analysis · IBIO · Life Sciences
The annual report confirms a $33.0 million net loss for fiscal 2026, up from $18.4 million, driven by an $11.3 million surge in R&D spending to $19.6 million as the company advanced its obesity pipeline. The company holds $88 million in cash and investments, extending its runway into fiscal 2028. The filing also discloses a new Amylin license agreement with AstralBio signed August 27, 2026, with a $750,000 upfront fee and up to $28 million in milestone payments, plus a full $5.0 million impairment of the legacy IBIO-101 oncology asset. Outstanding pre-funded warrants to purchase up to 95.8 million shares at $0.001 per share represent a significant overhang on the 64.3 million shares currently outstanding.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 30.2% of the 2009 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.11%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IBIO was trading at $1.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $69.5M. The 52-week trading range was $0.76 to $3.82. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.